A Phase 2 Study of the ALK Inhibitor Ensartinib for Patients With Melanomas Harboring ALK Alterations or Aberrant ALK Expression
Latest Information Update: 06 Feb 2025
At a glance
- Drugs Ensartinib (Primary)
- Indications Brain metastases; Malignant melanoma; Uveal melanoma
- Focus Therapeutic Use
Most Recent Events
- 04 Feb 2025 Planned End Date changed from 1 Jan 2025 to 1 Jan 2026.
- 04 Feb 2025 Planned primary completion date changed from 1 Jan 2025 to 1 Jan 2026.
- 01 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jan 2025.